deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00775073

Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001

Sponsor: Crolll Gmbh

Conditions Hepatocellular Carcinoma
Interventions Everolimus, Bevacizumab
Updated 6 times since 2017 Last updated: Apr 27, 2012 Started: Oct 31, 2008 Primary completion: Jan 31, 2011 Completion: Apr 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00775073, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by Crolll Gmbh, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Crolll Gmbh
  • Estimate, GmbH
  • Gerhard Treiber
  • Janssen Diagnostics, LLC
Data source: Treiber, Gerhard

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations